Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Home on the range where the buffalo roam -- Ignore unavailable to you. Want to Upgrade?

To: Boplicity who wrote (3623)	9/13/2001 12:50:22 PM
From: McNabb Brothers	Read Replies (2) \| Respond to of 13815

This may speed up the process you have been posting about: siliconinvestor.com Hank

To: Boplicity who wrote (3623)	9/13/2001 9:27:26 PM
From: Oak Tree	Read Replies (1) \| Respond to of 13815

ECOG 5397 Randomized, Double Blind, Placebo Controlled Phase III Evaluation of Cisplatin + Placebo Versus Cisplatin + C225 a Mouse/Human Monoclonal Antibody to the Epidermal Growth Factor Receptor in Patients with Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck This protocol is closed to acrual. The rumor is that it will be positive. The question is how positive. The rumor is also that there was little toxicity. Head and neck cancer is not a huge market of patients so even if it is positive it doen't make it a billion $ drug. Head and neck cancer is about 5% of cancer, and half are cured by radiation or surgery leaving only 2.5% with recurrent disease that need this drug to potentially supplement the chemotherapy.